Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion type Assertion NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_head.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion description "[However, after treatment of newborn hMRP8-AML1-ETO transgenic mice and their wild-type littermates with a strong DNA-alkylating mutagen, N-ethyl-N-nitrosourea, 55% of transgenic mice developed AML and the other 45% of transgenic mice and all of the wild-type littermates developed acute T lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_provenance.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion evidence source_evidence_literature NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_provenance.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion SIO_000772 11526243 NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_provenance.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion wasDerivedFrom befree-20140225 NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_provenance.
- NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_assertion wasGeneratedBy ECO_0000203 NP861472.RAV0wLF39CtjnSrxWcOhrLI321_bsXpRTrnX7_6qjTK_c130_provenance.